Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Philippe A. Cassier"'
Autor:
Anette Fält, Jean-Luc van Laethem, Peter Ellmark, Malin Carlsson, Karin Enell Smith, Maria Flärdh, Yago Pico de Coaña, Philippe A. Cassier
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A567-A567
BackgroundMitazalimab is a human CD40 agonistic antibody (IgG1) developed for cancer immunotherapy. Targeting CD40 provides an opportunity to kickstart the cancer-immunity cycle by priming and activating tumor-specific T cells.1 2 Furthermore, the ef
Autor:
Carola Ries, Priscila Camillo Teixeira, Dominik Rüttinger, Carlos Gomez-Roca, Wolfgang Jacob, Francesca Michielin, Martin Weisser, Georgina Meneses-Lorente, Jean-Marie Michot, Lauriane Eberst, Anna-Maria Jegg, Irina Klaman, Jean-Pierre Delord, Sabine Hoves, Galina Babitzki, Michael A. Cannarile, Philippe A. Cassier, Jean-Pascal Machiels, Konstanty Korski, Carl Watson, Tara C. Mitchell, Randolph Christen, Gaetan Catala, Dmitriy Zamarin
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol. 8, no. 2, p. e001153 [1-12] (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol. 8, no. 2, p. e001153 [1-12] (2020)
BackgroundThis phase Ib study evaluated the safety, clinical activity, pharmacokinetics, and pharmacodynamics (PD) of emactuzumab (anti-colony stimulating factor 1 receptor monoclonal antibody (mAb)) in combination with selicrelumab (agonistic cluste